CSIMarket
 


2seventy Bio Inc   (TSVT)
Other Ticker:  
 
 

TSVT's Revenue Growth by Quarter and Year

2seventy Bio Inc 's Revenue results by quarter and year




TSVT Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 10.68 56.18 -19.26 0.00
III Quarter September 12.03 13.41 19.26 0.00
II Quarter June 36.05 13.48 0.00 0.00
I Quarter March 41.62 8.43 0.00 0.00
FY   100.38 91.50 0.00 0.00



TSVT Revenue fourth quarter 2023 Y/Y Growth Comment
2seventy Bio Inc reported drop in Revenue in the fourth quarter 2023 by -80.98% to $ 10.68 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 2seventy Bio Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 463.33%.

Among companies who have reported fourth quarter 2023 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Revenue results in the fourth quarter 2023. While 2seventy Bio Inc ' s Revenue meltdown of -80.98% ranks overall at the positon no. 11 in the fourth quarter 2023.




TSVT Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -80.98 % - - -
III Quarter September -10.29 % -30.37 % - -
II Quarter June 167.43 % - - -
I Quarter March 393.71 % - - -
FY   9.71 % - - -

Financial Statements
2seventy Bio Inc 's fourth quarter 2023 Revenue $ 10.68 millions TSVT's Income Statement
2seventy Bio Inc 's fourth quarter 2022 Revenue $ 56.18 millions Quarterly TSVT's Income Statement
New: More TSVT's historic Revenue Growth >>


TSVT Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -11.19 % 318.94 % - -
III Quarter September -66.63 % -0.52 % - -
II Quarter June -13.38 % 59.91 % - -
I Quarter March -25.92 % - - -
FY (Year on Year)   9.71 % - - -




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #4
Overall #11

Revenue Y/Y Growth Statistics
High Average Low
808.23 % 463.33 % 9.72 %
(Sep 30 2023)   (Dec 31 2023)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #4
Overall #11
Revenue Y/Y Growth Statistics
High Average Low
808.23 % 463.33 % 9.72 %
(Sep 30 2023)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

2seventy Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
318.98 % 37.32 % -66.62 %
(Dec 31 2022)  


TSVT's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 2seventy Bio Inc realized drop in Revenue from the third quarter by -11.19% to $ 10.68 millions, from $ 12.03 millions declared in the previous quarter.

Even cyclical influence could not rescue the IV. Quarter for the 2seventy Bio Inc , Kayaan Saxena , Healthcare sector expert said, he detected additional challenges ahead for 2seventy Bio Inc and wrote that average sequential Revenue growth is at 37.32% for 2seventy Bio Inc .

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While 2seventy Bio Inc 's Revenue growth quarter on quarter, overall rank is 1717.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #216
Overall #1717
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #216
Overall #1717
Revenue Q/Q Growth Statistics
High Average Low
318.98 % 37.32 % -66.62 %
(Dec 31 2022)  


TSVT's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 2seventy Bio Inc reported drop in Revenue from the third quarter by -11.19% to $ 10.68 millions, from $ 12.03 millions declared in the previous reporting period.

Some cyclical influence were not able to salvage the IV. Quarter for the 2seventy Bio Inc , Kayaan Saxena , Healthcare sector expert said, he cited certan skepticism for the 2seventy Bio Inc 's direction.

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While 2seventy Bio Inc 's Revenue growth quarter on quarter, overall rank is 1717.


2seventy Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 100.39 $ 145.88 $ 147.25 $ 124.69 $ 91.50
Y / Y Revenue Growth (TTM) 9.72 % 808.23 % 572.06 % - -
Year on Year Revenue Growth Overall Ranking # 9 # 36 # 39 # 0 # 0
Seqeuential Revenue Change (TTM) -31.19 % -0.93 % 18.1 % 36.28 % 469.64 %
Seq. Revenue Growth (TTM) Overall Ranking # 11 # 3301 # 2951 # 2059 # 26




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, 2seventy Bio Inc 's cumulative twelve months Revenue were $ 100 millions, company would post below average annual Revenue growth of 469.64% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the 2seventy Bio Inc 's Revenue growth from the 12.03% growth in Sep 30 2023. Comparing the results with it's peers in Major Pharmaceutical Preparations industry, 2seventy Bio Inc 's trailing twelve months Revenue growth, were the second highest.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 9, from total ranking in previous quarter at 36.

Revenue TTM Q/Q Growth Statistics
High Average Low
808.23 %
463.33 %
9.72 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 2
Healthcare Sector # 3
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
808.23 %
463.33 %
9.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 4
S&P 500 # 11
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, 2seventy Bio Inc 's cumulative twelve months Revenue were $ 100 millions, company would post below average annual Revenue growth of 9.72% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the 2seventy Bio Inc 's Revenue growth from the 12.03% growth in Sep 30 2023. Comparing the results with it's peers in Major Pharmaceutical Preparations industry, 2seventy Bio Inc 's trailing twelve months Revenue growth, were the second highest.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 9, from total ranking in previous quarter at 36.

Revenue TTM Q/Q Growth Statistics
High Average Low
808.23 %
463.33 %
9.72 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 2
Healthcare Sector # 3
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
808.23 %
463.33 %
9.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 4
S&P 500 # 11




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TSVT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for TSVT's Competitors
Revenue Growth for 2seventy Bio Inc 's Suppliers
Revenue Growth for TSVT's Customers

You may also want to know
TSVT's Annual Growth Rates TSVT's Profitability Ratios TSVT's Asset Turnover Ratio TSVT's Dividend Growth
TSVT's Roe TSVT's Valuation Ratios TSVT's Financial Strength Ratios TSVT's Dividend Payout Ratio
TSVT's Roa TSVT's Inventory Turnover Ratio TSVT's Growth Rates TSVT's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Hookipa Pharma inc -5.38%$ -5.378 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com